Ocular Oncology Clinical Trials

Aura Biosciences : Belzupacap Sarotalocan
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Melanoma
This is a study on small choroidal melanoma using a novel nanoparticle treatment to eradicate the tumor, protect the patient’s life, save the eye, and hopefully lead to minimal damage to vision. This study involves 2 years follow up.

DRCR: Faricimab vs. Fluocinolone Acetonide vs. Observation
A Randomized Clinical Trial Evaluation of Intravitreal Faricimab Injections or Fluocinolone Acetonide Intravitreal Implants vs. Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy
This is a study for patients with choroidal melanoma who have been treated with plaque radiotherapy and explores various treatments to minimize radiation damage to the center of vision. The treatments involved in antiVEGF injections versus a steroid injections versus observation. This study involves 3 years follow up.

Ideaya: Darovasertib
(Neo)adjuvant IDE196 (darovasertib) in Patients with Localized Ocular Melanoma
This is a study for medium to large choroidal melanoma using a novel medication called darovasertib to shrink the melanoma prior to plaque radiotherapy or enucleation. The goal would be to reduce the radiation dose in those heading to plaque radiotherapy, and to shrink the melanoma enough that enucleation might not be necessary so that the eye could be treated with plaque radiotherapy. Additional goal would be to minimize metastatic disease. This study involves 2 years follow up.

Immunocore: Tebentafusp

Neoadjuvant Tebentafusp in Patients with Locally Advanced, Unresectable Primary Uveal Melanoma
This is a study for medium to large choroidal melanoma using a novel medication, called tebentafusp to shrink the melanoma, save the eye with plaque radiotherapy, and hopefully protect the patient from metastatic disease. The study involves 2 years follow up.

To learn more about the studies listed above, please contact:

Lisa Cotelesa
Ocular Oncology Study Coordinator
Email: lisac@shields.md
Phone: (215) 928-3108